ResMed
ResMed, News Corp bosses top CEO pay tables in 2023
The average realised pay for the chief executive of an ASX100 company in the 2023 financial year was 50 times what an average Australian worker earned.
- by Clancy Yeates
Latest
Another biotech boom? These Aussie giants are spending up big
Sleep treatments giant ResMed has been splashing cash on projects for growth as the sector spends up to secure post-pandemic growth.
- by Emma Koehn
Why this Aussie powerhouse is not worried about a global economic slowdown
The sleep treatments maker hopes to make its way through a global economic slowdown unscathed despite many of the markets it sells into facing serious headwinds.
- by Emma Koehn
ResMed eyes insomnia treatments after weathering chip shortage
The Australian sleep apnoea treatments maker has made two recent acquisitions focused on digital health.
- by Emma Koehn
The long and short of it
Investing
This Aussie giant delivered life-saving tech during COVID, but can it keep soaring?
Ventilator and sleep products maker ResMed has been on a rollercoaster for two years. Are its shares a good buy after their recent price falls?
- by Emma Koehn
Chip shortage curbs ResMed’s growth in face of surging demand
The medtech giant was forced to shave $US100 million off its revenue forecasts for capitalising on a competitor’s recall, with the stock falling 5 per cent.
- by Emma Koehn
‘Very, very challenging’: Costs hit ResMed as demand soars
Sleep treatment giant ResMed says rising freight costs and semiconductor chip shortages are curbing its ability to meet surging global demand for its devices.
- by Emma Koehn
The billionaire who won’t bid for Australian government health work
No debt and a focus on innovation has allowed software medical imaging company, Pro Medicus, to expand globally, turning its founders into billionaires.
- by Emma Koehn
ResMed ready to capitalise on ‘foot fault’ by rival Philips
Supply chain issues are lingering but ResMed boss Mick Farrell says the sleep treatment maker can secure long-term market share after a competitor’s major recall.
- by Emma Koehn
NYU accuses Resmed of patent breach over popular sleep apnoea product
New York University alleges Resmed has illegally used the university’s science to create the AirSense10 machine, one of its best-selling products.
- by Sarah Danckert
‘There is hope on the other side’: ResMed boss says Australia must keep fighting for vaccines
The US-based chief executive of one of Australia’s largest medtechs says the country must focus on both procuring doses and pitching their use to the public.
- by Emma Koehn
Original URL: https://www.theage.com.au/topic/rmd-1b8